ABSTRACT
Preeclampsia is becoming an increasingly common diagnosis in the developed world and remains a high cause of maternal and fetal morbidity and mortality in the developing world. Delay in childbearing in the developed world feeds into the risk factors associated with preeclampsia, which include older maternal age, obesity, and/or vascular diseases. Inadequate prenatal care partially explains the persistent high prevalence in the developing world. In this review, we begin by presenting the most recent concepts in the pathogenesis of preeclampsia. Upstream triggers of the well described angiogenic pathways, such as the heme oxygenase and hydrogen sulfide pathways, as well as the roles of autoantibodies, misfolded proteins, nitric oxide, and oxidative stress will be described. We also detail updated definitions, classification schema, and treatment targets of hypertensive disorders of pregnancy put forth by obstetric and hypertensive societies throughout the world. The shift has been made to view preeclampsia as a systemic disease with widespread endothelial damage and the potential to affect future cardiovascular diseases rather than a self-limited occurrence. At the very least, we now know that preeclampsia does not end with delivery of the placenta. We conclude by summarizing the latest strategies for prevention and treatment of preeclampsia. A better understanding of this entity will help in the care of at-risk women before delivery and for decades after.
Subject(s)
Pre-Eclampsia/metabolism , Pre-Eclampsia/therapy , Autoantibodies , Endoglin/metabolism , Female , Heme Oxygenase (Decyclizing)/metabolism , Humans , Hydrogen Sulfide/metabolism , Nitric Oxide/metabolism , Oxidative Stress , Postnatal Care , Practice Guidelines as Topic , Pre-Eclampsia/diagnosis , Pre-Eclampsia/etiology , Preconception Care , Pregnancy , Protein Folding , Receptor, Angiotensin, Type 1/immunology , Vascular Endothelial Growth Factor Receptor-1/metabolismABSTRACT
While the wide belief is that monoclonal antibodies, due to their large size, would not be able to penetrate the blood-brain barrier, we present a rare case of aseptic meningitis induced by intravenous cetuximab administration. A 58-year-old man with tonsillar squamous cell cancer presented with headache and fever, which started approximately 1â h after his first dose of cetuximab (loading dose of 400â mg/m(2) equalling 800â mg). CT scan of the head was non-revealing and laboratory tests including complete blood count, serum comprehensive metabolic panel and coagulation profile were within normal limits. Aseptic meningitis in the setting of cetuximab therapy has been reported on 6 previous occasions. Consistent with these prior reports, it is interesting to note that this case also occurred after administration of the initial higher loading dose of Cetuximab. This is of interest as Cetuximab is more frequently being dosed at 500â mg/m(2) (higher dose) every 2â weeks in colorectal cancer.